Surmodics to Present at Jefferies Healthcare Conference
Webcast is Live on Tuesday, June 7, at 4 p.m. (ET)
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Jun. 1, 2016-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced that Gary Maharaj, president and chief executive officer, and Andy LaFrence, vice president of finance and chief financial officer, will make a presentation to the investment community at the Jefferies Healthcare Conference in New York City on Tuesday, June 7, 2016, at 4 p.m. ET (3 p.m. CT).
A live audio webcast of the presentation will be available by going to the investor relations portion of the Company’s website at www.surmodics.com and clicking on the webcast icon. The webcast will be archived on the Company’s website for 90 days following the meeting.
About Surmodics, Inc.
Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic (IVD) tests and microarrays. Following two recent acquisitions of Creagh Medical and NorMedix, the Company is executing a key growth strategy for its medical device business by expanding to offer total intravascular product solutions to its medical device customers. The combination of proprietary surface technologies, along with enhanced device design, development and manufacturing capabilities, enables Surmodics to significantly increase the value it offers with highly differentiated intravascular solutions designed and engineered to the most demanding requirements. With this focus on offering total solutions, Surmodics’ mission remains to improve the detection and treatment of disease by using our technology to provide solutions to difficult medical device and diagnostic challenges. Surmodics is headquartered in Eden Prairie, Minnesota. For more information about the company, visit www.surmodics.com. The content of Surmodics’ website is not part of this press release or part of any filings that the company makes with the SEC.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160601005466/en/
Source: Surmodics, Inc.
Andy LaFrence, 952-500-7000